Developer docs
API playgroundTry for free, no card

Search company profiles

REGENXBIO

Full company profile

uuid0000qyb

Namestring
REGENXBIO
Legal namestring
REGENXBIO Inc.
Websiteurl
regenxbio.com
Company typeenum
Public
Founded yearint
2009
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, NAV vector platform, rare disease therapeutics, ophthalmic gene therapy, biopharmaceutical manufacturing
Industry5 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene therapy / AAV-based biopharmaceuticals
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Royalty Revenue from ZOLGENSMA
TypeLicensing Royalties
Description

REGENXBIO earns royalties from ZOLGENSMA (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy using NAV Technology, commercialized by Novartis. Royalty stream from product sales.

ir.regenxbio.com
2Partnership and Licensing Revenue
TypeLicensing Royalties
Description

Revenue from strategic partnerships including upfront payments, milestone payments, and ongoing royalties from AbbVie (ABBV-RGX-314 for retinal diseases) and Nippon Shinyaku (MPS programs). Includes $72.9 million upfront license payment from Nippon Shinyaku in 2025.

prnewswire.com
3Milestone Payments
TypeLicensing Royalties
Description

Expected $100 million milestone payment from AbbVie upon first patient dosing in Phase IIb/III NAAVIGATE study for diabetic retinopathy expected Q2 2026. Additional potential milestone payments tied to regulatory approvals and commercial milestones from partners.

prnewswire.com
4Royalty Bond Financing
TypeLicensing Royalties
Description

In May 2025, REGENXBIO closed a royalty bond agreement with Healthcare Royalty for up to $250 million, monetizing expected royalties and milestones from gene therapy products including ZOLGENSMA and others for rare and retinal diseases.

ir.regenxbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Operations, Personnel, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

REGENXBIO develops investigational AAV gene therapies for rare genetic and retinal diseases using its proprietary NAV Technology Platform of 100+ novel adeno-associated virus vectors. Its clinical pipeline includes RGX-202 for Duchenne muscular dystrophy, RGX-121 (Navsunli) for MPS II (Hunter syndrome), and ABBV-RGX-314 for wet AMD and diabetic retinopathy, supported by in-house cGMP manufacturing via the NAVXpress process. The platform is also licensed to other developers, including Novartis for the approved ZOLGENSMA therapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 93% of patients achieved primary endpoint of 10% microdystrophin expression at Week 12 in Phase 3 AFFINITY DUCHENNE trial (p<0.0001)
+3 more records
Product overview1 text field

REGENXBIO is a clinical-stage biotechnology company developing gene therapies using its proprietary NAV Technology Platform. The company's portfolio includes multiple therapeutic candidates: NAVSUULI (RGX-121) for MPS II, RGX-202 for Duchenne muscular dystrophy, and ABBV-RGX-314 (sura-vec) for wet AMD and diabetic retinopathy. These programs leverage the NAV AAV vector platform and are supported by the company's NAVXpress manufacturing process and in-house cGMP manufacturing capabilities.

Product and service5 records
1NAV Technology Platform
CategoryGene delivery technology platform
Description

REGENXBIO's proprietary library of 100+ novel AAV vectors used to develop gene therapies across multiple therapeutic areas and licensed to other gene therapy developers.

2RGX-121 (Navsunli)
CategoryAAV gene therapy — rare neurodegenerative disease
Description

One-time AAV gene therapy designed to deliver the human iduronate-2-sulfatase (IDS) gene to the CNS for the treatment of patients with Mucopolysaccharidosis Type II (Hunter syndrome).

3RGX-202
CategoryAAV gene therapy — neuromuscular disease
Description

One-time AAV gene therapy delivering a novel microdystrophin transgene with a functional C-Terminal domain for the treatment of Duchenne muscular dystrophy.

4ABBV-RGX-314 (sura-vec)
CategoryAAV gene therapy — retinal disease
Description

One-time AAV gene therapy designed to deliver sustained anti-VEGF antibody expression in the eye for patients with wet age-related macular degeneration and diabetic retinopathy.

5NAVXpress Manufacturing Process
CategoryBiopharmaceutical manufacturing process
Description

Proprietary scalable AAV vector manufacturing process enabling consistent yield and product purity for clinical and commercial cGMP production at REGENXBIO's Manufacturing Innovation Center.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Nippon Shinyaku / NS Pharma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Strategic partnership with Nippon Shinyaku for development and commercialization of REGENXBIO's MPS programs including RGX-121/Navsunli for Hunter syndrome (MPS II). REGENXBIO received $110 million upfront payment plus up to $700 million in potential development and commercial milestones. NS Pharma Inc. (subsidiary) holds U.S. commercialization rights for Navsunli.

investing.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Global partnership with AbbVie for development and commercialization of ABBV-RGX-314 (sura-vec) for wet age-related macular degeneration (wet AMD) and diabetic retinopathy. REGENXBIO received upfront payments and is eligible for up to $100 million milestone upon first patient dosing in NAAVIGATE study. AbbVie leads global commercialization with REGENXBIO manufacturing clinical supply.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

uniQure is a clinical-stage gene therapy company developing AAV-based therapeutics for hemophilia, Huntington's disease, and other indications, and is also a NAV Technology licensee. Both companies focus on AAV gene therapy platforms targeting rare diseases with high unmet need.

TypeDirect peer
Description

BioMarin developed and commercializes Roctavian, the first FDA-approved AAV gene therapy for hemophilia A. Both companies operate in the AAV gene therapy space targeting rare genetic diseases with one-time curative treatments.

TypeDirect peer
Description

Adverum is developing ixoberogene soroparvovec (Ixo-vec), an AAV-based gene therapy for wet AMD, directly competing with REGENXBIO's ABBV-RGX-314 in the ophthalmology gene therapy space. Both companies target the wet AMD market with one-time AAV gene therapy alternatives to chronic anti-VEGF injections.

TypeBroad incumbent
Description

Pfizer commercializes Beqvez, an FDA-approved AAV gene therapy for hemophilia B. As a large pharmaceutical incumbent with gene therapy capabilities, Pfizer competes broadly with REGENXBIO in the AAV gene therapy market while offering a wider portfolio of therapeutics.

TypeBroad incumbent
Description

Novartis commercializes ZOLGENSMA, the first FDA-approved NAV Technology-based gene therapy for SMA, generating royalty revenue for REGENXBIO. As a global pharmaceutical leader with established gene therapy commercialization, Novartis is both a partner and a broad incumbent in the gene therapy market.

TypeDirect peer
Description

Sarepta commercializes Elevidys, the only FDA-approved gene therapy for Duchenne muscular dystrophy and REGENXBIO's primary competitive rival in the DMD gene therapy space. Both companies are developing AAV-based microdystrophin therapies, making Sarepta the most direct clinical and commercial comparable.

TypeDirect peer
Description

4DMT is a clinical-stage gene therapy company developing tailored AAV vectors for ophthalmology and cardiology indications. Both companies develop novel AAV capsid platforms targeting multiple rare disease and ophthalmic indications.

TypeDirect peer
Description

Spark Therapeutics (acquired by Roche) developed and commercializes Luxturna, the first FDA-approved gene therapy for an inherited genetic disease (RPE65 mutation). Both companies develop AAV-based therapeutics for rare genetic diseases, with Jean Bennett on REGENXBIO's board having co-founded Spark.

TypeEmerging player
Description

Solid Biosciences is a clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy. As a direct competitor in the same indication with similar AAV-based microdystrophin approach, Solid is an emerging peer in the DMD gene therapy space.

TypeEmerging player
Description

Capricor is developing cell therapy (deramiocel) and exosome-based treatments for Duchenne muscular dystrophy. While using a different therapeutic modality, Capricor targets the same patient population as RGX-202 and represents an emerging player in the DMD treatment landscape.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

REGENXBIO

Gene therapy / AAV-based biopharmaceuticalsregenxbio.com

REGENXBIO firmographics

Firmographics
Name
REGENXBIO
Legal name
REGENXBIO Inc.
Website
https://regenxbio.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

REGENXBIO industry classification

Industry
Product category
Gene therapy / AAV-based biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy
  • NAV vector platform
  • Rare disease therapeutics
  • Ophthalmic gene therapy
  • Biopharmaceutical manufacturing

Where REGENXBIO is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

REGENXBIO business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Infrastructure

Revenue model

  1. Royalty Revenue from ZOLGENSMA: REGENXBIO earns royalties from ZOLGENSMA (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy using NAV Technology, commercialized by Novartis. Royalty stream from product sales.
  2. Partnership and Licensing Revenue: Revenue from strategic partnerships including upfront payments, milestone payments, and ongoing royalties from AbbVie (ABBV-RGX-314 for retinal diseases) and Nippon Shinyaku (MPS programs). Includes $72.9 million upfront license payment from Nippon Shinyaku in 2025.
  3. Milestone Payments: Expected $100 million milestone payment from AbbVie upon first patient dosing in Phase IIb/III NAAVIGATE study for diabetic retinopathy expected Q2 2026. Additional potential milestone payments tied to regulatory approvals and commercial milestones from partners.
  4. Royalty Bond Financing: In May 2025, REGENXBIO closed a royalty bond agreement with Healthcare Royalty for up to $250 million, monetizing expected royalties and milestones from gene therapy products including ZOLGENSMA and others for rare and retinal diseases.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

REGENXBIO product offering

Product offering

Core offering

REGENXBIO develops investigational AAV gene therapies for rare genetic and retinal diseases using its proprietary NAV Technology Platform of 100+ novel adeno-associated virus vectors. Its clinical pipeline includes RGX-202 for Duchenne muscular dystrophy, RGX-121 (Navsunli) for MPS II (Hunter syndrome), and ABBV-RGX-314 for wet AMD and diabetic retinopathy, supported by in-house cGMP manufacturing via the NAVXpress process. The platform is also licensed to other developers, including Novartis for the approved ZOLGENSMA therapy.

Product overview

REGENXBIO is a clinical-stage biotechnology company developing gene therapies using its proprietary NAV Technology Platform. The company's portfolio includes multiple therapeutic candidates: NAVSUULI (RGX-121) for MPS II, RGX-202 for Duchenne muscular dystrophy, and ABBV-RGX-314 (sura-vec) for wet AMD and diabetic retinopathy. These programs leverage the NAV AAV vector platform and are supported by the company's NAVXpress manufacturing process and in-house cGMP manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • NAV Technology Platform REGENXBIO's proprietary library of 100+ novel AAV vectors used to develop gene therapies across multiple therapeutic areas and licensed to other gene therapy developers.
  • RGX-121 (Navsunli) One-time AAV gene therapy designed to deliver the human iduronate-2-sulfatase (IDS) gene to the CNS for the treatment of patients with Mucopolysaccharidosis Type II (Hunter syndrome).
  • RGX-202 One-time AAV gene therapy delivering a novel microdystrophin transgene with a functional C-Terminal domain for the treatment of Duchenne muscular dystrophy.
  • ABBV-RGX-314 (sura-vec) One-time AAV gene therapy designed to deliver sustained anti-VEGF antibody expression in the eye for patients with wet age-related macular degeneration and diabetic retinopathy.
  • NAVXpress Manufacturing Process Proprietary scalable AAV vector manufacturing process enabling consistent yield and product purity for clinical and commercial cGMP production at REGENXBIO's Manufacturing Innovation Center.

Quantifiable outcome

  • 93% of patients achieved primary endpoint of 10% microdystrophin expression at Week 12 in Phase 3 AFFINITY DUCHENNE trial (p<0.0001)
  • +3 more outcomes

Companies that use REGENXBIO

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles3 records

REGENXBIO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

REGENXBIO partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Nippon Shinyaku / NS PharmacoreStrategic or Co-development Partner · 1 January 2025Strategic partnership with Nippon Shinyaku for development and commercialization of REGENXBIO's MPS programs including RGX-121/Navsunli for Hunter syndrome (MPS II). REGENXBIO received $110 million upfront payment plus up to $700 million in potential development and commercial milestones. NS Pharma Inc. (subsidiary) holds U.S. commercialization rights for Navsunli.
  • AbbViecoreStrategic or Co-development Partner · 1 January 2021Global partnership with AbbVie for development and commercialization of ABBV-RGX-314 (sura-vec) for wet age-related macular degeneration (wet AMD) and diabetic retinopathy. REGENXBIO received upfront payments and is eligible for up to $100 million milestone upon first patient dosing in NAAVIGATE study. AbbVie leads global commercialization with REGENXBIO manufacturing clinical supply.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

REGENXBIO competitors and assessment

Company assessment

Direct peers

  • uniQure: uniQure is a clinical-stage gene therapy company developing AAV-based therapeutics for hemophilia, Huntington's disease, and other indications, and is also a NAV Technology licensee. Both companies focus on AAV gene therapy platforms targeting rare diseases with high unmet need.
  • BioMarin Pharmaceutical: BioMarin developed and commercializes Roctavian, the first FDA-approved AAV gene therapy for hemophilia A. Both companies operate in the AAV gene therapy space targeting rare genetic diseases with one-time curative treatments.
  • Adverum Biotechnologies: Adverum is developing ixoberogene soroparvovec (Ixo-vec), an AAV-based gene therapy for wet AMD, directly competing with REGENXBIO's ABBV-RGX-314 in the ophthalmology gene therapy space. Both companies target the wet AMD market with one-time AAV gene therapy alternatives to chronic anti-VEGF injections.
  • Sarepta Therapeutics: Sarepta commercializes Elevidys, the only FDA-approved gene therapy for Duchenne muscular dystrophy and REGENXBIO's primary competitive rival in the DMD gene therapy space. Both companies are developing AAV-based microdystrophin therapies, making Sarepta the most direct clinical and commercial comparable.
  • 4D Molecular Therapeutics: 4DMT is a clinical-stage gene therapy company developing tailored AAV vectors for ophthalmology and cardiology indications. Both companies develop novel AAV capsid platforms targeting multiple rare disease and ophthalmic indications.
  • Spark Therapeutics: Spark Therapeutics (acquired by Roche) developed and commercializes Luxturna, the first FDA-approved gene therapy for an inherited genetic disease (RPE65 mutation). Both companies develop AAV-based therapeutics for rare genetic diseases, with Jean Bennett on REGENXBIO's board having co-founded Spark.

Broad incumbents

  • Pfizer: Pfizer commercializes Beqvez, an FDA-approved AAV gene therapy for hemophilia B. As a large pharmaceutical incumbent with gene therapy capabilities, Pfizer competes broadly with REGENXBIO in the AAV gene therapy market while offering a wider portfolio of therapeutics.
  • Novartis: Novartis commercializes ZOLGENSMA, the first FDA-approved NAV Technology-based gene therapy for SMA, generating royalty revenue for REGENXBIO. As a global pharmaceutical leader with established gene therapy commercialization, Novartis is both a partner and a broad incumbent in the gene therapy market.

Emerging players

  • Solid Biosciences: Solid Biosciences is a clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy. As a direct competitor in the same indication with similar AAV-based microdystrophin approach, Solid is an emerging peer in the DMD gene therapy space.
  • Capricor Therapeutics: Capricor is developing cell therapy (deramiocel) and exosome-based treatments for Duchenne muscular dystrophy. While using a different therapeutic modality, Capricor targets the same patient population as RGX-202 and represents an emerging player in the DMD treatment landscape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

REGENXBIO social profiles

Digital presence

REGENXBIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

REGENXBIO leadership team

Management profile

Number of profiles

Profiles18 records

REGENXBIO funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

REGENXBIO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REGENXBIO

What does REGENXBIO do?

REGENXBIO develops investigational AAV gene therapies for rare genetic and retinal diseases using its proprietary NAV Technology Platform of 100+ novel adeno-associated virus vectors. Its clinical pipeline includes RGX-202 for Duchenne muscular dystrophy, RGX-121 (Navsunli) for MPS II (Hunter syndrome), and ABBV-RGX-314 for wet AMD and diabetic retinopathy, supported by in-house cGMP manufacturing via the NAVXpress process. The platform is also licensed to other developers, including Novartis for the approved ZOLGENSMA therapy.

Is REGENXBIO a public or private company?

REGENXBIO is a public company. It is classified as public and is currently operating.

When was REGENXBIO founded?

REGENXBIO was founded in 2009. It employs 251 to 500 people.

Where is REGENXBIO based?

REGENXBIO is headquartered in Rockville, United States, in the North America region.

How does REGENXBIO make money?

Four revenue lines are on record. Royalty Revenue from ZOLGENSMA is the primary driver. The others are partnership and Licensing Revenue, milestone Payments and royalty Bond Financing.

Who are REGENXBIO's main competitors?

Direct peers on record are uniQure, BioMarin Pharmaceutical, Adverum Biotechnologies, Sarepta Therapeutics, 4D Molecular Therapeutics and Spark Therapeutics. Broad incumbents are Pfizer and Novartis. Emerging players are Solid Biosciences and Capricor Therapeutics.

Does REGENXBIO have an API?

No public API is recorded for REGENXBIO.

What industry is REGENXBIO in?

REGENXBIO's product category is Gene therapy / AAV-based biopharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaREGENXBIO Inc. (RGNX) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptREGENXBIO's CEO and CMO presented at Stifel's 2026 Healthcare Conference, discussing RGX-314 gene therapy data. The company highlighted its partnership with AbbVie and noted the study is among the largest gene therapy trials ever conducted.Simply Wall StREGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Pretty Bullish On The Stock After Recent ResultsREGENXBIO's shares rose 5.8% to $7.62 after Q3 results, with revenue of $9.2m missing forecasts by 14% but statutory losses per share of $0.62 beating estimates by 53%. Analysts now forecast 2027 revenue of $212m and losses of $2.54 per share, up from prior estimates, and the consensus price target rose 5.2% to $24.55.The Motley FoolREGENXBIO (RGNX) Q3 2026 Earnings Call TranscriptREGENXBIO reported Q3 2026 net loss of $40.7 million and cash of $251 million, down from $61.9 million loss and $241 million cash in Q3 2025. The company plans a BLA submission for RGX-202 in Q1 2027 and expects sura-vec pivotal data later this year.Seeking AlphaRegenxbio outlines RGX-202 full BLA filing in Q1 2027 with cash runway late into Q4 2027 (NASDAQ:RGNX)Regenxbio's Q3 2026 earnings call outlined a full BLA filing for RGX-202 in Q1 2027, with U.S. accelerated-approval expected in the second half of 2027. The company reported $251 million in cash and a runway into Q4 2027, while sura-vec wet AMD pivotal results are expected this quarter.Seeking AlphaREGENXBIO Inc. (RGNX) Q3 2026 Earnings Call TranscriptREGENXBIO reported its third-quarter 2026 financial and operating results on November 5, 2026, with the press release available on its website. The call included forward-looking statements about financial outlook, regulatory and product development plans, and risks that could cause actual results to differ from forecasts.ChartmillREGENXBIO (NASDAQ:RGNX) Q3 2026: Narrower Loss Offsets Revenue Miss as Shares Rise PremarketREGENXBIO reported Q3 2026 revenue of $9.16 million, below the $11.09 million consensus, while its non-GAAP loss per share was -$0.62, narrower than the -$1.31 consensus. The stock rose 3.76% in premarket trading, with analysts projecting Q4 revenue of about $33.5 million and full-year 2026 revenue of about $166.3 million.PR NewswireREGENXBIO Reports Third Quarter 2026 Financial Results and Operational HighlightsREGENXBIO reported Q3 2026 net loss of $40.7 million and cash of $251.0 million. It expects topline data from sura-vec AMD trials in Q4 2026 and a RGX-202 BLA submission in Q1 2027. The company also noted a $38 million litigation settlement gain.PR NewswireREGENXBIO Reports Third Quarter 2026 Financial Results and Operational HighlightsREGENXBIO reported Q3 2026 net loss of $40.7 million and cash of $251.0 million. It expects topline data from sura-vec AMD trials in Q4 2026 and a RGX-202 BLA submission in Q1 2027. The company also noted a $38 million litigation settlement gain.YahooRegenxbio (RGNX) Expected to Beat Earnings Estimates: Should You Buy?Regenxbio is expected to report a quarterly loss of $1.35 per share, down 12.5% year-over-year, with revenues of $9.6 million, down 67.7%. The Zacks Earnings ESP of +6.53% and Zacks Rank #2 suggest a likely earnings beat.Stock TitanREGENXBIO sets Nov. 5 Q3 2026 conference callREGENXBIO will host a conference call on November 5, 2026, to discuss its third-quarter 2026 financial results and operational highlights. The call is scheduled for that date, with no further details provided.